What is Cardio Diagnostics?
Cardio Diagnostics is a biotechnology firm dedicated to enhancing the accessibility, personalization, and precision of cardiovascular disease prevention and early detection. The company's strategic objective is to shift medical care for cardiovascular conditions from a reactive model to a proactive one. By leveraging epigenetics-based technologies powered by artificial intelligence, Cardio Diagnostics aims to usher in an era of Precision Cardiovascular Medicine, making prevention and early detection the standard of care. Their flagship solutions, developed in collaboration with leading scientists and clinicians, include the Epi+Gen CHD test, designed to provide clinicians with a more accurate assessment of individual patient risk profiles for cardiovascular disease.
How much funding has Cardio Diagnostics raised?
Cardio Diagnostics has raised a total of $11.4M across 1 funding round:
Debt
$11.4M
Debt (2023): $11.4M, investors not publicly disclosed
What's next for Cardio Diagnostics?
The recent major strategic investment, alongside the company's overall funding trajectory, suggests Cardio Diagnostics is poised for significant scaling and further development of its innovative diagnostic technologies. This capital infusion is likely to accelerate the expansion of its AI-driven epigenetics platform and broaden the clinical adoption of its cardiovascular risk assessment tools. The company's focus on proactive, personalized medicine aligns with emerging trends in healthcare, positioning it for substantial growth and impact in the fight against cardiovascular disease.
See full Cardio Diagnostics company page
